Clinic Conversation of the Week: How to Talk to Patients About the BENEFIT Trial in Multiple Myeloma
The BENEFIT trial, which studied isatuximab, lena…
Oncology Data Advisor · i3 Health
November 12, 20245m 36s
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?